Hypercholesterolaemia is a significant modifiable risk factor for cardiovascular disease (CVD), a leading cause of morbidity and mortality in the UK. GPs play a pivotal role in identifying and managing elevated cholesterol levels, aiming to reduce the burden of CVD through effective primary and secondary prevention strategies. This article provides a practical guide to the diagnosis, assessment and management of hypercholesterolaemia within the primary care setting, emphasising a person-centred approach, to improve patient outcomes.
Get full access to this article
View all access options for this article.
References
1.
BaigentCBlackwellLEmbersonJ, et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet376(9753): 1670–1681. DOI: 10.1016/S0140-6736(10)61350-5.
2.
BhattDLStegPGMillerM, et al. (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine380(1): 11–22. DOI: 10.1056/NEJMoa1812792.
DurandAMorganCLTinsleyS, et al. (2023) Familial hypercholesterolaemia in UK primary care: a Clinical Practice Research Datalink study of an under-recognised condition. British Journal of General Practice74(740): e174–e182. DOI: 10.3399/BJGP.2023.0010.
9.
FredricksonDSLevyRJLeesRS (1967) Fat transport in lipoproteins – an integrated approach to mechanisms and disorders. New England Journal of Medicine276(1): 34–44. DOI: 10.1056/NEJM196701052760107.
MachFBaigentCCatapanoAL, et al. (2020) ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal41(1): 111–188. DOI: 10.1093/eurheartj/ehz455.
15.
MachFKoskinasKCRoetersJE, et al. (2025). 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal46(42): 4359–4378. DOI: 10.1093/eurheartj/ehaf190.
16.
MunjalAKaufmanEJ (2023) Arcus aenilis. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing. Available at: www.ncbi.nlm.nih.gov/books/NBK554370 (accessed 12 February 2026).
NICE (2019) Familial hypercholesterolaemia: identification and management. Available at: www.nice.org.uk/guidance/cg71 (accessed 1 October 2025).
23.
NICE (2022) Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. Available at: www.nice.org.uk/guidance/ta805 (accessed 1 October 2025).
24.
NICE (2023) Cardiovascular disease: risk assessment and reduction, including lipid modification. Available at: www.nice.org.uk/guidance/ng238 (accessed 1 June 2025).
25.
NissenSELincoffAMBrennanD, et al. (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine388(15): 1353–1364. DOI: 10.1056/NEJMoa2215024.
26.
RaiHCoughlanJJO’CallaghanD, et al. (2025) Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study. Irish Journal of Medical Science194(6): 2085–2094. DOI: 10.1007/s11845-025-04096-y.
27.
RuscicaMSirtoriCRCarugoS, et al. (2022) Bempedoic acid: for whom and when. Current Atherosclerosis Reports24(10): 791–801. DOI: 10.1007/s11883-022-01054-2.
28.
SabatineMSGuiglianoRPKeechAC, et al. (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine376(18): 1713–1722. DOI: 10.1056/nejmoa1615664.
29.
ShihKHerzNSheikhA, et al. (2025) Economic burden of cardiovascular disease in the United Kingdom. European Heart Journal – Quality of Care and Clinical Outcomes11(5): 678–690. DOI: 10.1093/ehjqcco/qcaf011.
